Pharma

Your Article Summary

See Latest Articles

Randomized phase 2 study of imc-a12 for her2-expressing advanced breast cancer commences patient enrollment
ImClone Sytems, 11/20/08

ImClone Systems Incorporated, a global leader in the development and commercialization of novel antibodies to treat cancer, announced that its disease-directed randomized Phase 2 clinical trial of IMC-A12 in patients with previously treated HER2-expressing locally advanced or metastatic breast cancer has commenced patient enrollment. IMC-A12 is ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer MaterialScience develops drug-releasing coatings for medical applications
BayNews International, 03/19/10

First Publication of Data from Pivotal Clinical Trial for Medtronic Deep Brain Stimulation Therapy for Epilepsy Published Today in Epilepsia
Medtronic, 03/19/10

CEL-SCI Completes Validation Of Manufacturing Facility Allowing It To Commence Manufacturing Of Multikine
CEL-SCI, 03/19/10

 See all of Research & Development